Key Development
Vietnam has significantly expanded its drug-registration review capacity. But the more important question is whether higher processing volume can evolve into a regulatory system that delivers consistent, timely and scientifically reliable decisions.
According to results released on October 6, 2026, the advisory council responsible for pharmaceutical and medicinal-ingredient registration reviewed 31,941 dossiers between August 13, 2023 and August 13, 2026, nearly three times the 10,597 recorded during the preceding term.
The total comprised 14,811 new-registration applications, 15,287 renewals and 1,843 variation or supplementary applications. The council held 105 meetings across 152 working days.
Approximately 70% of new-registration dossiers received favorable council assessments, compared with 64.2% in the previous period. The corresponding rates were approximately 90% for renewals and 80% for variations.
However, the council acknowledged that dossier quality and assessment consistency have not fully kept pace with the increase in volume. That makes the next phase of reform more complicated than simply reviewing additional applications.
Why It Matters
- Drug registration is part of pharmaceutical supply security. Delays can disrupt manufacturing, import planning and continuity of marketed portfolios.
- Regulatory uncertainty creates financial costs. Unpredictable decisions complicate product launches, inventory management and investment allocation.
- Review volume is not patient access. A successful regulatory pathway must ultimately lead to commercially available products.
- Speed without consistency can create rework. Multiple clarification cycles may offset the benefits of faster initial processing.
Healthcare Insight Analysis
Healthcare Insight believes the nearly 32,000-dossier milestone demonstrates improved regulatory throughput, but does not yet establish regulatory predictability.
These are fundamentally different capabilities.
Throughput measures how many applications a regulatory system can evaluate.
Predictability measures whether an adequately prepared dossier moves through the system within a reasonably foreseeable period, under transparent requirements and consistent technical standards.
For pharmaceutical companies, the second metric may be commercially more important.
A manufacturer can plan around a rigorous approval process if documentation requirements and decision timelines are sufficiently clear.
Uncertainty, however, can delay launches, tie up working capital and complicate the allocation of regional manufacturing and commercial resources.
The next bottleneck may therefore move upstream.
Instead of being primarily about organizing more assessment meetings, the challenge becomes improving submission quality, reducing avoidable deficiencies and standardizing assessment practices.
Circular 12/2025/TT-BYT, effective July 1, 2025, forms part of Vietnam’s updated drug-registration framework. However, the increase in dossiers during 2023–2026 cannot be attributed exclusively to this regulation.
The more useful approach is to evaluate the full pharmaceutical access pathway:
Dossier preparation → technical assessment → advisory recommendation → marketing authorization → commercial launch → patient access.
Every transition matters.
A medicine may receive a favorable council recommendation without immediately obtaining marketing authorization. An authorized product may also remain unavailable because of manufacturing, commercial, distribution or procurement constraints.
This distinction is particularly important for healthcare executives.
The reported approval percentages refer to favorable advisory assessments, not necessarily final authorizations or products successfully launched.
Nor do aggregate dossier counts reveal whether the total pending backlog declined.
Without information on application inflows, outstanding cases and review-time distributions, it is difficult to determine whether the increase represents a permanent productivity improvement, backlog clearance or a combination of both.
Healthcare Insight therefore sees the next competitive frontier as regulatory process quality.
Useful performance indicators would include median end-to-end review time, first-cycle acceptance, repeated deficiency requests, renewal continuity and the interval between authorization and actual market availability.
These measures would connect administrative performance with commercially and clinically meaningful outcomes.
Market Implications
Domestic pharmaceutical manufacturers: regulatory-documentation capabilities can become a competitive advantage, particularly for portfolio expansion and renewal continuity.
Multinational pharma: greater predictability could strengthen market-entry planning and support decisions to register innovative therapies in Vietnam.
Hospitals and distributors: more reliable authorization continuity may reduce one source of pharmaceutical supply disruption.
Regulatory technology providers: digital submission systems, structured validation and workflow tracking represent potential opportunities.
ANALYTICAL MATRIX
| Dimension | Current Signal | Next Challenge | KPI to Watch |
| Review capacity | 31,941 dossiers | Sustain performance | Median review time |
| New applications | ~70% favorable assessment | Improve submission quality | First-cycle acceptance |
| Renewals | ~90% favorable assessment | Maintain supply continuity | Renewal continuity |
| Assessment | Major volume expansion | Standardize review | Rework rate |
| Patient access | Not measured by dossier count | Convert authorization into supply | Approval-to-market time |
The next success milestone should not simply be another record number of dossiers reviewed.
It should be a system in which pharmaceutical companies understand the path to market, regulators maintain scientific rigor and patients experience more reliable access to essential and innovative medicines.
At that point, regulatory efficiency becomes more than administrative reform — it becomes part of Vietnam’s pharmaceutical competitiveness.